INSPIREMD INC

NSPR represents InspireMD, Inc., a medical device company focused on developing and commercializing stent systems for the treatment of vascular and coronary artery disease. Its primary product is the CGuard carotid embolic prevention stent system, designed to prevent embolic events during carotid artery stenting procedures. The company also develops the MGuard embolic protection stent. InspireMD operates in the healthcare sector within the medical devices industry and markets its products in various international regions.

Historical performance for NSPR can be reviewed through its price chart, which shows how the stock has traded over various periods since its public listing. Like many small-cap medical device stocks, NSPR has experienced significant price fluctuations driven by clinical trial results, regulatory developments, and financing activities. For precise historical price data, including annual returns and key milestones, refer to the historical performance section on this NSPR stock page.

Evaluating NSPR's valuation requires considering that the company may not yet be profitable, which limits the usefulness of traditional earnings-based metrics like the P/E ratio. Investors often look at price-to-sales, price-to-book, and enterprise value relative to revenue or pipeline potential. Comparing these metrics to peer medical device companies and assessing cash burn, revenue trajectory, and product milestones can provide context. The latest valuation data for NSPR is available on this page.

To buy NSPR stock, you need a brokerage account that offers access to U.S. equity markets. Once your account is funded, you can place a buy order for NSPR shares through your broker's trading platform, specifying the number of shares and order type, such as market or limit order. NSPR is listed on the Nasdaq exchange, so it can be purchased during regular trading hours. Fractional shares may be available depending on your broker.

Analyzing NSPR's financial performance involves reviewing its quarterly and annual reports, including the income statement, balance sheet, and cash flow statement. Key areas to examine include revenue growth, gross margins, operating expenses, and cash burn rate, which are critical for a medical device company that may be investing heavily in research and development. Earnings releases and investor presentations often provide updates on product adoption and clinical milestones. These filings are accessible through the SEC and the company's investor relations site.

NSPR faces risks typical of small-cap medical device companies, including regulatory hurdles for its stent products, clinical trial outcomes, and reliance on a limited product portfolio. Commercial adoption of CGuard and MGuard may be slower than expected, and the company may need additional financing, which could dilute shareholders. Competition from larger medical device firms and changes in healthcare reimbursement policies also pose challenges. Additionally, NSPR's share price can be volatile due to its small market capitalization and low trading volume.